The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or radiation and/or systemic therapies.
Recruiting
The investigational immunotherapy is being studied in a group of patients to see if it is safe and effective.
EligibilityAll patients who enroll in the trial will receive medication while on the study.
Clinical trial sites are places such as hospitals or clinics where the trial is being conducted.
See LocationsOnly a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or radiation and/or systemic therapies.
Sign up to receive an email alert when a clinical trial location in your area begins accepting patients.
When speaking to your doctor, please have the trial reference number available. You can also call 1-888-577-8839 for more information.
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.
